China’s Xi speaks with Trump by phone, discusses Taiwan and bilateral ties
Investing.com - Procept Biorobotics (NASDAQ: PRCT) reported third quarter EPS of $-0.38, $0.03 better than the analyst estimate of $-0.41. Revenue for the quarter came in at $83.3M versus the consensus estimate of $80.83M.
Guidance
Procept Biorobotics sees FY 2025 revenue of $325.50M versus the analyst consensus of $326.50M.
Procept Biorobotics's stock price closed at $35.02. It is down -8.83% in the last 3 months and down -63.31% in the last 12 months.
Procept Biorobotics saw 1 positive EPS revisions and 6 negative EPS revisions in the last 90 days. See Procept Biorobotics's stock price’s past reactions to earnings here.
According to InvestingPro, Procept Biorobotics's Financial Health score is "good performance".
Check out Procept Biorobotics's recent earnings performance, and Procept Biorobotics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar
